No Data
No Data
Mabwell (Shanghai) Bioscience Co., Ltd. (SHSE:688062) Insiders, Who Hold 42% of the Firm Would Be Disappointed by the Recent Pullback
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Express News | Mabwell Announces Nmpa Approval to Initiate Clinical Trial of Novel B7-H3-Targeting ADC for Advanced Solid Tumors in Combination With Pd-1 Inhibitor
Maiwei Biotech: Maiwei Biotech 2024 Annual Report
Maiwei Biotech: Summary of Maiwei Biotech\'s 2024 Annual Report
Maiwei Biotech 2024 Annual Report